Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment

Journal of Viral Hepatitis

Volumn 21, Issue 6, 2014, Pages 439-446

  Singh, A K ^a   Sharma, M K ^a   Hissar, S S ^a   Gupta, E ^a   Sarin, S K ^a  

^a INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

Author keywords

chronic hepatitis; HBeAg; HBsAg; HBV; seroconversion; tenofovir

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; PHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; DRUG MONITORING; HEPATITIS B, CHRONIC; MIDDLE AGED; TIME; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG MONITORING; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; TIME FACTORS; YOUNG ADULT;

EID: 84901060223     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12149     Document Type: Article

References (12)

1. Moucari R, Mackiewicz V, Lada O, et al,. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology (Baltimore, MD) 2009; 49: 1151-1157.
2. Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen BE, Janssen HL,. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449-454.
3. Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF,. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 2011; 106 (10): 1766-1773.
4. Jung YK, Kim JH, Lee YS, et al,. Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir. J Clin Gastroenterol 2010; 44: 653-657.
5. Heathcote EJ, Marcellin P, Buti M, et al,. Three-year efficacy and safety of Tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-143.
6. Marcellin P, Heathcote EJ, Buti M, et al,. HBsAg kinetics in patients with chronic hepatitis B (CHB) treated with Tenofovir disoproxil fumarate (TDF) for up to 4 years. J Hepatol 2011; 54: 740A.
7. Nguyen T, Locarnini S,. Hepatitis: monitoring drug therapy for hepatitis B-a global challenge? Nat Rev Gastroenterol Hepatol 2009; 6: 565-567.
8. TrehanPati N, Kotillil S, Hissar SS, et al,. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with Tenofovir disoproxil fumarate. J Clin Immunol 2011 Jun; 31 (3): 509-520.
9. Marcellin P, Gane E, Buti M,. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate treatment for chronic hepatitis B: a five year open label study. Lancet 2013; 381: 468-475.
10. Kirschberg O, Schuttler C, Repp R, Schaefer S,. A multiplex-PCR to identify hepatitis B virus-genotypes A-F. J Clin Virol 2004; 29: 39-43. (Pubitemid 37524085)
11. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL,. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011; 204: 415-418.
12. Park MS, Kim BK, Kim KS, et al,. Antiviral efficacies of currently available rescue therapies for multi-drug resistant chronic hepatitis B. Clin Mol Hepatol 2013; 19: 29-35.